Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, today announced top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5.0% lifitegrast ophthalmic solution.
Shire Plc (SHP) agreed to buy ViroPharma Inc. (VPHM) for about $4.2 billion to gain treatments for rare diseases and ease dependence on its best-selling Vyvanse pill for attention deficit hyperactivity disorder.
Shire (SHPG +0.8%) is out with top-line results from OPUS-2 (that's lifitegrast in dry eye patients). Although the ophthalmic solution met its eye dryness co-primary endpoint, it did not meet the reduced corneal staining endpoint.
Shire PLC (SHPG), a Dublin-based biopharmaceutical company, was founded in 1986. It typically caters to diverse medical needs through research and development, but it also produces, sells and distributes pharmaceutical products.